MIRA Pharmaceuticals, Inc. Stock price

Equities

MIRA

US60458C1045

Biotechnology & Medical Research

Market Closed - Nasdaq 20:59:46 01/03/2024 GMT 5-day change 1st Jan Change
1.04 USD +3.47% Intraday chart for MIRA Pharmaceuticals, Inc. +3.99% -0.96%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2021 - Sales 2022 - Capitalization 15.37M 1.21B
Net income 2021 -2M -158M Net income 2022 -7M -553M EV / Sales 2021 * -
Net cash position 2021 * - 0 Net cash position 2022 * - 0 EV / Sales 2022 * -
P/E ratio 2021 *
-
P/E ratio 2022 *
-
Employees -
Yield 2021 *
-
Yield 2022 *
-
Free-Float 43.94%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.47%
1 week+3.99%
Current month+3.47%
1 month+11.82%
3 months-72.63%
6 months-83.17%
Current year-0.96%
More quotes
1 week
0.96
Extreme 0.9616
1.10
1 month
0.85
Extreme 0.85
1.54
Current year
0.79
Extreme 0.79
1.54
1 year
0.79
Extreme 0.79
7.98
3 years
0.79
Extreme 0.79
7.98
5 years
0.79
Extreme 0.79
7.98
10 years
0.79
Extreme 0.79
7.98
More quotes
MIRA Pharmaceuticals, Inc. is a clinical development stage biopharmaceutical company. The Company is focused on the development and commercialization of molecular synthetic cannabinoid analog for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. The Company is developing its product candidate, MIRA1a, for the treatment of neuropsychiatric, inflammatory and neurologic diseases and disorders. MIRA1a is a synthetic cannabinoid analog for treating anxiety and chronic pain by striking a balance between the beneficial effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) by targeting the cannabinoid type 1 and type 2 (CB1 and CB2) receptors.
More about the company
  1. Stock
  2. Equities
  3. Stock MIRA Pharmaceuticals, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW